Add like
Add dislike
Add to saved papers

[Antitumor effector cells in recombinant IL-2 activated tumor infiltrating lymphocytes from human solid cancers].

Tumor infiltrating lymphocytes (TIL) isolated from 46 human solid cancers, including 24 renal cell carcinoma (RCC), 15 cancers of digestive organs and 7 other malignancies, were cultured with 1000 units/ml of recombinant interleukin-2 (rIL-2). Induction of activated TIL was achieved in 41 cases (89.1%). Their antitumor characteristics and cell surface antigen expressions were examined using 4 hr 51Cr release assay and flow cytometric analysis in long-term culture. Cytotoxic activity of rIL-2 activated TIL derived from RCC was significantly higher than that from other tumors, but the TIL could lyse various types of cells and specificity for autologous tumor cells could not be demonstrated in any of the cultures. Though CD3+ lymphocytes were predominant in all fresh TIL preparations, antitumor activity of rIL-2 activated TIL correlated with the increase of a cell population expressing the Leu19 antigen without the CD3 antigen. Depletion of selected cell types from TIL cultures using direct complement dependent cytolysis followed by cytotoxicity tests identified the Leu19+ CD3- CD16- cells as the major effector population. CD3-, CD16+ NK cells held minor antitumor cytotoxicity and there was no detectable cytotoxic activity in the CD3+ T lymphocytes.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app